BIOMARKER:

CLDN18.2 positive

Entrez ID:

Related biomarkers:

‹

›

CLDN18.2 positive CLDN18.2 positive	Gastric Cancer Gastric Cancer	CLDN18.2 positive CLDN18.2 positive	Gastric Cancer Gastric Cancer	CT041 Sensitive: C2 – Inclusion Criteria	CT041 Sensitive: C2 – Inclusion Criteria
CLDN18.2 positive CLDN18.2 positive	Solid Tumor Solid Tumor	CLDN18.2 positive CLDN18.2 positive	Solid Tumor Solid Tumor	MIL93 Sensitive: C2 – Inclusion Criteria	MIL93 Sensitive: C2 – Inclusion Criteria
CLDN18.2 positive CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	CT041 Sensitive: C2 – Inclusion Criteria	CT041 Sensitive: C2 – Inclusion Criteria
CLDN18.2 positive CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CLDN18.2 positive CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CT041 Sensitive: C3 – Early Trials	CT041 Sensitive: C3 – Early Trials
CLDN18.2 positive CLDN18.2 positive	Gastric Cancer Gastric Cancer	CLDN18.2 positive CLDN18.2 positive	Gastric Cancer Gastric Cancer	CLDN18.2-targeted CAR-T immunotherapy Sensitive: D – Preclinical	CLDN18.2-targeted CAR-T immunotherapy Sensitive: D – Preclinical
CLDN18.2 positive CLDN18.2 positive	Pancreatic Cancer Pancreatic Cancer	CLDN18.2 positive CLDN18.2 positive	Pancreatic Cancer Pancreatic Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical